Evidence map›Paper›PMID 39417168›Full record

ArticleAmerican journal of cancer research2024

A novel NR4A2-HuR axis promotes pancreatic cancer growth and tumorigenesis that is inhibited by NR4A2 antagonists.

Sneha Johnson, Zuhua Yu, Xi Li, Mehrdad Zarei, Ali Vaziri-Gohar, Miok Lee, Srijana Upadhyay, Heng Du, Mahsa Zarei, Stephen Safe

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sneha JohnsonDepartment of Veterinary Physiology and Pharmacology, Texas A&M University College Station, TX, USA.
Zuhua YuDepartment of Veterinary Physiology and Pharmacology, Texas A&M University College Station, TX, USA.
Xi LiDepartment of Veterinary Physiology and Pharmacology, Texas A&M University College Station, TX, USA.
Mehrdad ZareiDepartment of Surgery, University Hospitals Cleveland, OH, USA.
Ali Vaziri-GoharDepartment of Surgery, University Hospitals Cleveland, OH, USA.
Miok LeeDepartment of Veterinary Physiology and Pharmacology, Texas A&M University College Station, TX, USA.
Srijana UpadhyayDepartment of Veterinary Physiology and Pharmacology, Texas A&M University College Station, TX, USA.
Heng DuDepartment of Medicine, Brigham and Women's Hospital and Harvard Medical School Boston, MA, USA.
Mahsa ZareiDepartment of Veterinary Physiology and Pharmacology, Texas A&M University College Station, TX, USA.
Stephen SafeDepartment of Veterinary Physiology and Pharmacology, Texas A&M University College Station, TX, USA.

Funding

Texas A&M Center for Environmental Health Research (TiCER)P30ES029067 · NIEHS · TEXAS A&M UNIVERSITY · PI Sakhila Banu · 2019 to 2026
$13.0M
NIEHS NIH HHS P30 ES029067
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) patients' express higher levels of the orphan Nuclear Receptor 4A2 (NR4A2, NURR1) compared to normal pancreas and NR4A2 is a prognostic factor for patient survival. Knockdown of NR4A2 by RNA interference (RNAi) inhibited cell proliferation, invasion, and migration. RNA sequencing performed in NR4A2

Indexed as

HuRIDH1NR4A2NR4A2 antagonist treatmentPancreatic cancer

Identifiers

PMID39417168
PMCPMC11477821

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.